The new role will focus on establishing a long term unified vision for BenevolentAI’s technology Platform to enable the discovery and development of novel and more effective medicines
London, 21 January 2022, BenevolentAI, a leading clinical-stage AI drug discovery company, today announced the promotion of Daniel Neil to Chief Technology Officer (CTO), effective immediately.
Since joining BenevolentAI in 2017, Daniel has been responsible for scaling the company’s New York team and building technologies that form the foundation of BenevolentAI’s target identification products. In his new role, Daniel will assume leadership of BenevolentAI’s technology function and develop and execute the company’s long term technology strategy. Daniel will work side-by-side with BenevolentAI’s Chief Science Officer to build industry-leading and state-of-the-art technology that empowers scientists to discover and develop new therapies for complex, untreated or inadequately treated diseases.
“Daniel is a proven leader who has had a phenomenal impact on the business to date,” said Joanna Shields, CEO of BenevolentAI. “He is a trusted advisor to me and the entire Executive Leadership Team, and has transformed our AI and machine learning function into a best-in-class team. Our thriving New York office is a credit to his ability. His strong leadership skills, strategic experience and deep knowledge of the business make him the ideal choice to lead our long-term technology strategy."
Daniel Neil, CTO of BenevolentAI, commented: “I am excited and honoured to transition into this new leadership role at BenevolentAI. What BenevolentAI has achieved to date is unique in the industry and I strongly believe the company is well-positioned for success. I look forward to enabling future growth by leveraging the right blend of people, process, product and innovation, so we can build transformative technologies and deliver new medicines to patients.”
After completing his BS in Biomedical Computation at Stanford University, Daniel obtained his Ph.D. in Switzerland at ETH Zurich and the University of Zurich, where he focused his research on machine learning and neuroscience and is the author of more than forty publications and patents.
BenevolentAI is a leading, clinical-stage AI drug discovery company. Through the combined capabilities of its AI Platform, scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. BenevolentAI has a consistently proven track-record of scientifically validated discoveries. The BenevolentAI Platform™ powers a growing in-house pipeline of over 20 drug programmes, spanning from target discovery to clinical studies, and it maintains successful commercial collaborations with leading pharmaceutical companies. BenevolentAI also identified Eli Lilly's baricitinib as a repurposing drug candidate for COVID-19, which has been authorised for emergency use by the FDA. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.
Rajin Kang - VP Communications
Back to press releases and in the media